On March 16, YIDU TECH (02158) continued its vigorous share repurchase program, spending more than HK$11 million that day. This move maintains the company's recent trend of high-frequency, substantial buybacks, demonstrating management's strong confidence in the firm's intrinsic value and the long-term prospects of the AI healthcare sector. So far in 2026, the company's buyback activities have been consistent and impressive, with the cumulative number of repurchases steadily increasing. Total expenditure has exceeded HK$210 million, and the proportion of treasury shares has reached nearly 4.5%, consistently setting new company records. Following long-standing giants like AIA, YIDU TECH is one of the very few companies to reach this significant threshold, with a buyback intensity that leads among small to mid-cap stocks in the Hong Kong market, highlighting growing market recognition. The confidence behind this strong repurchase activity stems from the company's solid business execution and innovative breakthroughs. Recently, YIDU TECH launched its Yidu Clinical Evidence Intelligence Agent, which precisely enhances clinical diagnosis and medical research, addressing gaps in AI-driven evidence-based clinical decision-making. Simultaneously, the company is actively engaging in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, deepening practical collaborations in medical AI, supporting the implementation of real-world research, and improving the quality of primary healthcare. This strategy drives growth both in capital market expectations and in core business operations.